• If you are wondering whether Crinetics Pharmaceuticals at around US$37.49 is a bargain or already pricing in a lot of optimism, you are asking the right question for a valuation check.
• The stock has seen a 21.3% decline over the last 30 days and is down 19.8% year to date, even though its 1 year return is 8.8% and its 3 year return is 117.3%.
• Recent attention on Crinetics has focused on its progress as a pharmaceuticals and biotech company, including ongoing development work that shapes investor expectations for its future pipeline. That context helps explain why the share price can react sharply as new data points or clinical updates reach the market.
• Right now Crinetics has a valuation score of 2 out of 6, so next we will look at what traditional valuation methods say about the stock, then close with a more complete way to think about value that goes beyond a single score.

Crinetics Pharmaceuticals scores just 2/6 on our valuation checks. See what other red flags we found in the full valuation breakdown.

Approach 1: Crinetics Pharmaceuticals Discounted Cash Flow (DCF) Analysis

A Discounted Cash Flow, or DCF, model takes projections of a company’s future cash flows and discounts them back to today using a required rate of return, in order to estimate what the business might be worth at present.

For Crinetics Pharmaceuticals, the model used is a 2 Stage Free Cash Flow to Equity approach. The latest twelve month free cash flow is a loss of $386.6 million. Analyst and extrapolated estimates indicate free cash flow remains negative through 2028, then turns positive in 2029 at $131.7 million and reaches $559.7 million by 2030. Beyond the initial analyst horizon, Simply Wall St extrapolates cash flows out to 2035, still in $ millions rather than $ billions.

Discounting all those projected cash flows back to today, the DCF model provides an estimated intrinsic value of about $464.66 per share. Compared with a recent share price around $37.49, the model output suggests the stock is 91.9% undervalued based on these cash flow assumptions.

Result: UNDERVALUED

Our Discounted Cash Flow (DCF) analysis suggests Crinetics Pharmaceuticals is undervalued by 91.9%. Track this in your watchlist or portfolio, or discover 48 more high quality undervalued stocks.

Approach 2: Crinetics Pharmaceuticals Price vs Book

For profitable companies, price based multiples help you see what investors are paying today for each unit of earnings, sales, or net assets. Price to book, or P/B, is especially useful for comparing how the market values a company relative to the accounting value of its equity.

Growth expectations and risk matter here. Higher expected growth and lower perceived risk tend to support higher “normal” P/E or P/B ratios, while slower growth or higher uncertainty usually point to lower multiples being reasonable.

Crinetics currently trades on a P/B of 3.96x. That sits above the Pharmaceuticals industry average of 2.09x and also above the peer group average of 3.54x. On those simple comparisons, the shares look more expensive than many similar names.

Simply Wall St’s Fair Ratio concept goes a step further. It is a proprietary estimate of what a suitable P/B multiple could be after considering factors such as earnings growth, profit margins, industry, market cap, and specific risks. Because it folds these elements into one number, it can be more informative than a basic peer or industry comparison that treats all companies as if they had the same outlook and risk profile.

In this case, there is no Fair Ratio figure available, so you cannot draw a firm conclusion on whether the current 3.96x P/B is rich, cheap, or about right relative to that benchmark.

Result: ABOUT RIGHT

P/B ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 18 top founder-led companies.

Upgrade Your Decision Making: Choose your Crinetics Pharmaceuticals Narrative

Earlier we mentioned that there is an even better way to understand valuation. On Simply Wall St’s Community page you can use Narratives, where you write a clear story about Crinetics Pharmaceuticals, link that story to your own revenue, earnings and margin assumptions, and see how those flow into a fair value. You can then compare that fair value to the current price, with the system updating your Narrative automatically when news or earnings arrive. For example, one investor might build a more cautious view closer to US$45, while another leans into the optimistic case around US$108. You can quickly see which story you feel more comfortable with.

Do you think there's more to the story for Crinetics Pharmaceuticals? Head over to our Community to see what others are saying!

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.